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Summary.-Leukaemia L 1210 cells preincubated in vitro with neuraminidase
preparations derived either from Vibrio cholerae (VCN) or Clostridium perfringens
(CPN) lost their i.p. transplantability for normal DBA/2 mice. This loss of trans-
plantability could not be observed when the enzyme treated cells were implanted in
mice whose immune status was suppressed by prior cyclophosphamide treatment.
Mice receiving i.p. implants of enzyme treated leukaemia cells developed immunity
to subsequent i.p. challenge with untreated L 1210 cells but not to a challenge with
Ehrlich ascites tumour cells. The magnitude of immune response evoked by L 1210
cells preincubated with 250 u/ml of VCN or 35 ,ug/ml of CPN for 60 minutes was of
relatively low level when compared with the immunity induced by leukaemia cells
preincubated with50 u/ml ofVCN or 15 ,ug/ml of CPNfor30 or60 minutes. Evidence
is presented to show that the induced immunity can be transferred passively with the
serum and with the peritoneal cells from the mice implanted with VCN treated
L 1210 cells to normal DBA/2 mice. The significance of the neuraminidase induced
increase in the immunogenicity of treated tumour cells is discussed.
LYMPHOCYTIC leukaemia L 1210 which
arose in a DBA/2 mouse following skin
paintings with methylcholanthrene (Law
et al., 1949) is a strain specific leukaemia
since it grows only in DBA/2 or related
hybrid hosts. A single leukaemia cell is
capable of producing progressive leu-
kaemia and ultimate death of the DBA/2
hosts (Skipper, Schabel and Wilox, 1967).
However in spite of its strain specificity a
weak immune response against this leu-
kaemia is present even in DBA/2 mice
(Mihich, 1969). This leukaemia is also
included as one of the 3 standard cancer
chemotherapy screens (Leiter, Abbott and
Schepartz, 1964).
Bagshawe and Currie (1968) have pre-
viously reported that intraperitoneal (i.p.)
implantation of L 1210 cells pretreated
with Vibrio cholerae neuraminidase (VCN)
failed to kill intact (C57BLfDBA/2F1)
mice whereas the pre-irradiated mice died
of leukaemia. Furthermore, the recipi-
ents of VCN treated L 1210 cells showed
resistance to subsequenti.p. challengewith
8 x 103 untreated L 1210 cells. In view
of the above findings, it was decided to
investigate more intensively the effect of
neuraminidase preparations derived from
Vibrio cholerae and Clostridiumperfringens
on the transplantability of L 1210 cells in
the DBA/2 (isogenic) mice. It was also
considered worthwhile to study the nature
and magnitude of the immune response
evoked by enzyme treated L 1210 cells,
and to ascertain whether the induced
immunity can be transferred by serum or
the peritoneal exudate cells (PE) to
normal DBA/2 mice.
MATERIAL AND METHODS
Mice.-Inbred, female mice of strain
DBA/2 (SPF), 20-25 g (purchased from
Bomholtghrd, Denmark), were used through-NEURAMINIDASE INDUCED LOSS IN TRANSPLANTABILITY IN DBA/2MLCE 107
out this study. The mice were housed in
plastic cages and provided with tap water and
pelleted diet.
Leukaemia cells. Leukaemia L 1210 cells
grown in suspension culture were obtained
from Professor D. W. van Bekkum of the
Radiological Institute Rijswijk, Netherlands.
This line was originally developed from the
tumour maintained in DBA/2 C57 BL mice.
In our laboratory it was maintained in ascitic
form by weekly i.p. transplantation of 0-1 ml
of 1: 10 dilution of ascitic fluid (approxi-
mately 2 x 106 cells) in female DBA/2 mice.
From a series of preliminary experiments it
w-as concluded that i.p. inoculation of 10-100
cells ofthis line could produce progressive and
fatal leukaemia in female DBA/2 hosts.
Immunosuppression of mice by cyclo-
phosphamide treatment.-The drug cyclo-
phosphamide is known for its immunosuppres-
sive effect in mice (Berenbaum and Brown,
1964). The drug was administered suspended
in saline as a single i.p. injection at a dose of
250 mg/kg one day before the implantation of
leukaemia cells. This dose of the drug did
not exert any toxic effect on the mice.
Neuraminidase preparations.-Neuram-
inidase prepared from the filtrate of Vibrio
cholerae (VCN) was obtained from Behring-
w-erke AG., Marburg-Lahn, West Germany, in
vials containing 500 units/ml. (One unit of
VCN releases 1 ,tg of iN-acetylneuraminic acid
from human cxl-acid glycoprotein substrate at
a pH of 5-5 in 15 min at 37°C.) Another
neuraminidase preparation derived from
Clostridium perfringens (CPN) and obtained
from General Biochemicals, Chagrin Falls,
Ohio, USA, was prepared to contain 0 5 units/
mg (one unit causes the release of 1 jumol of
sialic acid per min from bovine submaxillary
mucin at 37°C).
The enzyme solutions were diluted in
50 mmol/l sodium acetate buffer (pH 5-5)
containing 0-900 sodium chloride solution and
1 mg/ml calcium chloride. The enzyme pre-
parations could be inactivated ifnecessary by
heating at 100°C for 10 min.
In vitro incubation of L 1210 cells with
neuraminidase. One u-eek old ascitic tumours
were harvested under aseptic conditions and
diluted 1: 1 with tissue culture medium 199
(TCM 199) (Grand Island Biological Co.,
New York). The cells were washed twice
with TCM 199 and then suspended in distilled
water to lyse red cells and w ashed again with
TCM 199. The washed cells were then
incubated with neuraminidase preparationis
in sodium acetate buffer (pH 5.5) at a final
concentration of 50 u or 250 u/105 cells in the
case of VCN, and 15 ,tg or 35 jug/ml/105 cells
in the case of CPN. The incubation w,-as
carried out with occasional shaking at 37°C for
a period of 30 or 60 min, after which the cells
were wzashed twice with TCM 199 before final
suspension in TCM 199. The viability of the
cells was checked by the trypan blue exclusion
test; cell counts were made in a haemocyto-
meter and the suspension adjusted by dilution
to the desired concentrations. Neuramini-
dase treatment did not affect the viabilitv of
the cells as assessed by the dye exclusion test
and this is in accord with the observations of
previous investigators (Bagshawe and Currie.
1968; Sanford and Codington, 1971; Wood-
ruff and Gesner, 1969). Controls included
untreated L 1210 cells and L 1210 cells incu-
bated either with sodium acetate buffer
alone, or with heat inactivated neuraminidase
preparations.
Implantation of L 1210 cells in mice.-The
test preparations of L 1210 cells were inocu-
lated either i.p. or s.c. at desired concentra-
tions in a total volume of0-1 ml/mouse. The
inoculated mice were kept under daily
observation and the lethality wNas recorded.
Preparation ofperitoneal exudate cells (PE)
and serum for transfer experiments.-Three
days before the collection of PE the donor
mice were injected with 1 ml of a 3 0/ starch
suspension i.p./mouse. The exudate was
collected by rinsing the peritoneal cavity of
each mouse with 2-3 ml ofTCAI 199. Pooled
yields of freshly harvested PE cells from
5 mice w,ere used in transfer experiments.
Aliquots of the cell suspensions were counted
in a haemocytometer for determination ofthe
total numbers. The cell population consisted
of about 85-900o macrophages. The blood
of the donors w%Aas collected by cardiac
puncture, allowNed to clot and the fresh sera
from a total of 15 mice was pooled and used in
the transfer tests.
RESULTS
N\Teuraminidase induced loss of the trans-
plantability of L 1210 cellsfor J)BA/2 mice
Separate groups of 10-20 female DBA/
2 mice were given an i.p. injection of 105
L 1210 cells (0.1 ml/mouse) which had
received various types of pre-treatmentsK. K. SETHI AND H. BRANDIS
TABLE I.-Effect of in vitro Incubation of L 1210 Cells with Neuraminidase Preparation
(VCN or CPN) on their Subsequent Growth* in Normal DBA/2 Mice and those
Immunosuppressed by Prior Cyclophosphamide Treatment
Normal mice Immunosuppressed mice
80-days AST*** 80-days AST
Inl vitro treatmenit of L 1210 cells (105 cells) survivors** (days) survivors (days)
None (untreated) . . . . . 0/8 (0%) 10-0
Sodium acetate buffer . . . . 0/5 (0%) 9-4
VCN (50 u/ml) for 30mi . . . . 14/20 (70%) 20-3 . 0/10 (0%) 10-0
VCN (50 u/ml) for 60mi . . . 16/20 (80%) 19-5 . 0/10 (0%) 11-4
VCN inactivated (50 u/ml) for 30 min . . 0/5 (0%) 10-0 . 0/5 (0%) 11 -0
VCN inactivated (50 u/ml) for 60 min . 0/5 (0%) 9-0
VCN (250 u/ml) for 30mi . 20/20 (100%) 0/5 (0%) 10-2
VCN (250 u/ml) for 60mi . . 20/20 (100%) . 0/10 (0%/) 10-7
VCN inactivated (250 u/ml) for 30 min 0/5 (0%) 9-2
CPN (15 pg/ml) for 30mi. . 16/20 (80%) 21-0 . 0/7 (0%) 9-2
CPN (15 jig/ml) for 60mi. . 17/20 (85%) 18-5 . 0/5 (0%) 12 -0
CPN inactivated (15 ,pg/ml) for 30 min 0/8 (0%) 12-2
CPN (35 pg/ml) for 30min. . . . 16/20 (80%) 20-0 . 0/5 (0%) 10-0
CPN (35 ,ug/ml) for 60 min. . . 18/20 (90%) 15-0 . 0/5 (0%/) 11-0
CPN inactivated (35 ,ug/ml) for 60 min 0/6 (0%) 10-2
* L 1210 pretreated in various ways were injected i.p. (105 cells/mouse) into separate groups of 5-20 mice.
** No. surviving/total No. of mice; the figures in parentheses represent the percentages of the survivors.
*** AST = Average survival time (only those mice that died on or before day 80).
VCN Vibrio cholerae neuraminidase.
CPN Clostridium perfrinqens neuraminidase.
(Table I). The mice receiving untreated
leukaemia cells or leukaemia cells incu-
bated in sodium acetate buffer showed no
survivors over an observation period of
80 days. The percentage of mice killed
was not affected by prior incubation of
L 1210 cells with heat-inactivated pre-
parations of VCN or CPN. In contrast,
the percentages of survivors in the groups
which received L 1210 cells preincubated
with 50 u/ml of VCN or 15 ,ug/ml of CPN
for 30 min were 70 and 80 respectively.
In addition, the survival time of mice
which died of leukaemia was significantly
prolonged; the average survival time
(AST) was 20-3, 21-0 and 10-0 days for
VCN treated, CPN treated and control
(untreated) mice respectively. The sur-
vival times after treatment with L 1210
cells preincubated with 50 u/ml ofVCN or
15,ug/ml of CPN for 60 min were more
or less identical with those obtained when
the leukaemia cells were treated for 30
min. The experimental groups of
mice receiving i.p. implants of 105 L 1210
pre-incubated with 250 u/ml of VCN for
either 30 min or 60 min gave 100%
survivors. Mice receiving i.p. implants of
leukaemia cells preincubated with 35 ,ag/
ml of CPN for 30 min or 60 min gave 80
and 90% survivors respectively. How-
ever, whenthe VCN orCPNtreated L 1210
cells were implanted in the peritoneal
cavity of mice whose immune status was
suppressed by prior cyclophosphamide
treatment, there was no evidence of the
rejection ofimplants and all the mice died.
Also, in the control groups ofnormal mice
inoculated with 103 or 105 L 1210 cells all
the mice died from tumour growth.
Fate of VCN-treated L 1210 cells in the
peritoneal cavity ofDBA/2 mice
In order to follow the fate of enzyme
treated leukaemia cells in the peritoneal
cavity of normal DBA/2 mice, 15 mice
were inoculated i.p. with 105 VCN treated
L 1210 cells/mouse (105 cells/50 u VCN/ml
for 30 min). After the inoculation peri-
toneal washings were made at various
intervals, by rinsing the peritoneal cavity
with 1-2 ml of TCM 199. These suspen-
sions (1 ml) were inoculated into groups of
15-20 normal mice. The washings har-
vested 4-6 days after the implantations of
enzyme treated cells failed to induce
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TABLE II.-Induction ofImmunoprotection in DBA12 Mice against L 1210
Leukaemia by Neuraminidase Treated L 1210 Cells
Total
Mice surviving previous i.p. no. of
inoculation of mice
L 1210 cells preincubated with . 14
VCN (50 u/ml/105 cells) for
30 min
L 1210 cells preincubated with . 16
VCN (50 u/ml/105 cells) for
60 min
L 1210 cells preincubated with 20
VCN (250 u/ml/105 cells) for
30 min
L 1210 cells preincubated with . 20
VCN (250 u/ml/105 cells) for
60 min
L 1210 cells preincubated with . 16
CPN (15 ,ug/ml/105 cells) for
30 min
L 1210 cells preincubated with . 17
CPN (15 jug/ml/105 cells) for
60 min
L 1210 cells preincubated with . 16
CPN (35 ,ug/ml/105 cells) for
30 min
L 1210 cells preincubated with . 18
CPN (35 ,ug/ml/105 cells) for
60 min
Mice (normal controls) . 25
* 40 days survivors (No./Total).
tumours whereas the early washings
regularly caused the death of the inocu-
lated mice. This suggests that beyond
4-6 days viable tumour cells were absent
in the washings, since the presence ofvery
few tumour cells would be capable of
producing fatal leukaemia.
Immunoprotection induced byenzyme treated
L 1210 cells
The different groups of mice surviving
i.p. implantation of L 1210 cells pre-
treated with neuraminidase preparations
were subsequently challenged with graded
doses ofL 1210 cells s.c. or i.p. at intervals
of either 3 weeks or 6 weeks following the
implantation ofenzyme treated leukaemia
cells (Table II). One group of animals
which had survived primary implantation
of enzyme treated L 1210 cells was chal-
lenged with 104 Ehrlich ascites tumour
cells (EAT). Groups of normal mice
wereinoculated with correspondinginocula
Interval
between Challenge close and route
primary ,
injection 103 105
and challenge -,
(weeks) i.p. s.c. i.p. s.c.
3 . 3/3* 3/3 3/3
6 . 3/3 2/2
3 . 4/4
6 . 2/2
3/3 3/3
104 EAT
cells
(i.p.)
0/4
3 . 3/3 3/3 4/4 3/3
6 . 3/3 2/2 2/2
3 . 3/5 4/5 1/5 0/5
3 . 3/3
6 . 4/4
3 . 3/3
6 . 3/3
4/4 3/3 2/2
4/4
4/4
3 . 3/3 2/2 4/4
6 . 3/3 2/2
0/3
2/2
3 . 2/5 3/5 0/3 1/5
. 0/5 0/5 0/5 0/5 0/5
i.p. or s.c. and included as controls. Mice
which had survived a primary i.p. injec-
tion of L 1210 cells preincubated with
50 u/ml of VCN or 15 ,cg/ml of CPN for
either 30 min or 60 min were completely
protected against i.p. or s.c. challenge
doses of 103 or 105 cells, whether chal-
lenged 3 weeks or 6 weeks after the im-
plantation of enzyme treated leukaemia
cells. Mice surviving a primary implanta-
tion of L 1210 cells preincubated with
250 u/ml of VCN or 35 ,ug/ml of CPN for
30 min also showed complete protection
when challenged at intervals of 3 weeks or
6 weeks with either 103 or 105 cells.
However, mice surviving an i.p. implanta-
tion of L 1210 cells preincubated with
250 u/ml of VCN or 35 ,ug/ml of CPN for
60 min showed survival rates of only 60%
and 40% respectively when challenged i.p.
with 103 cells 3 weeks following the
implantation of enzyme treated L 1210
cells. If the challenge of mice pretreatedK. K. SETHI AND H. BRANDIS
TABLE III.-Growth of L 1210 Cells in Normal DBA/2 Mice Pretreated with Serum or
Peritoneal Exudate Cells (PE) from Mice which Survived i.p. Implantation of VCN-
treated L 1210 Cells
Material transferred (i.p.)
1 ml serum (donors received 105
VCN treated L 1210 cells, i.p.)
1 ml serum (donors received 105
VCN treated L 1210 cells, i.p.)
1 ml serum (donors, normal
DBA/2 mice)
PE cells (donors received 105
VCN treated L 1210 cells, i.p.)
PE cells (donors received 105
VCN treated L 1210 cells, i.p.)
PE cells (donors normal DBA/2
mice)
1 ml TCM 199
Interval between
injection of VCN
treated cells and
collection of serum
or (PE) cells*
3 weeks
2 months
3 weeks
2 months
Ratio of
(PE) cells
to L 1210
cells
800: 1
200: 1
100 :1
10: 1
800: 1
200: 1
100 :1
10: 1
800: 1
* Peritoneal exudate cells (PE) contained about 85-90% macrophages.
i.p. challenge with
104 L 1210 cells
80 days AST
survivors (days)
8/8
0/10 10 2
0/5
15/15
9/10
6/10
0/10
7/12
6/10
4/10
0/10
2/12
11*0
14-0
16 0
10-0
19.0
16-0
9 0
10-0
0/5 10 0
with neuraminidase-treated L 1210 cells
(105 cells, 50u/mlfor 30min) was madei.p.
with 104 EAT cells no protection could be
observed.
Fate of the challenge inoculum in the
peritoneal cavity of immune mice
It was of interest to ascertain the fate
of a challenge with normal L 1210 cells
implanted in the peritoneal cavity of mice
surviving the primary inoculum of enzyme
treated L 1210 cells. Attempts were
therefore made to isolate L 1210 cells
from the peritoneal cavity of challenged
mice that did not develop tumours 30 days
following the challenge. The peritoneal
washings of the survivors were injected
i.p. (1-2 ml/mouse) into a group of 20
normal mice. None of the treated mice
developed tumours. This implies that the
immunity has a lethal rather than static
effect on L 1210 cells used for challenge.
Passive transfer of immunity with serum
and PE cells
Twenty mice were given i.p. admini-
stration of 105 VCN treated L 1210 cells
(50 u/ml/105 cells for 60 min) per mouse.
After intervals of 3 weeks or 2 months
following the implantation, groups of
10 mice were used for preparing the serum
and PE cells for passive transfer experi-
ments. The results presented in Table III
indicate that sera collected 3 weeks
following the implantation of enzyme
treated L 1210 cells when administered
i.p. (1 ml per mouse) 30 min before the
challenge with 104 untreated L 1210 cells
protected the mice completely. The
serum did not protect mice which received
i.p. injection of 104 EAT cells. The
recipients of sera from normal donors
showed 100% lethality. The protection
by serum against L 1210 leukaemia was
not observed in the samples of serum col-
lected 2 months after the implantation of
enzyme treated leukaemia cells.
PE cells collected 3 weeks after the
implantation of enzyme treated cells
when transferred i.p. 30 min before tumour
challenge completely rejected the growth
of 104 L 1210 cells (the ratio between leu-
kaemia cells to PE cells being 1: 800).
The administration of PE cells of immune
mice and L 1210 cells at ratios of 200: 1,
l.p.
challenge
with 104
EAT cells
40 days
survivors
0/6
0/5
0/5
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100: 1 and 10: 1 resulted in 9000, 60%
and 000 survivors respectively among the
normal recipients. The PE cells collected
2 months after the implantation ofenzyme
treated cells protected 7 out ofa total of 12
mice against a challenge dose of 104 L 1210
cells when the ratio between L 1210 cells
and PE cells was 1 : 800. The 5 mice
which died of ascites tumour had an AST
of 19 days compared with a 10-11 days
survival period of controls. When the
leukaemia cells and PE cells were admini-
stered at ratios of 1: 200, 1: 100 and
1 : 10, the survival rates among the
recipients were 60, 40 and 000 respectively.
The PE cells from normal donors failed to
confer a protection in normal DBA/2 mice
against 104 L 1210 cells when the ratio
between leukaemia cells to PE cells was
1: 800. The PE cells of immune mice
were unable to protect the recipients
against a challenge with 104 EAT cells
when the ratio of PE cells to EAT cells
was 800: 1.
DISCtTSSION
Bagshawe and Currie (1968) have previ-
ously found that L 1210 cells preincubated
with VCN lost the property to killnormally
susceptible (C 57BL/DBA/2F1) mice
following i.p. inoculation, whereas all pre-
irradiated mice died from tumour growth.
The results of the present study confirm
that the in vitro incubation of L 1210 cells
with either VCN or CPN destroyed their
capacity to induce tuLmours when implant-
ed i.p. in intact isogenic DBA/2 mice. On
the other hand, the mice whose immune
status was suppressed by prior treatment
with the drug cyclophosphamide, permit-
ted the progressive growth of enzyme
treated leukaemia cells, resulting eventu-
ally in their death.
Neuraminidase-induced alteration in
tumour transplantability has been re-
ported in a variety of other tumour host
systems (Sanford, 1967; Lindenmann and
Klein, 1967; Currie and Bagshawe, 1968,
1969). However, the mechanism(s) which
might account for the failure of enzyme
treated tumouir cells to grow in otherwise
susceptible hosts is not yet clear. It has
been suggested that neuraminidase treat-
ment leads to an increase in the immuno-
genicity ofthe treated cells, resLilting in an
effective recognition by the host immunie
system (Bagshawe and Currie, 1968;
Currie and Bagshawe, 1969; Sanford,
1967; Bekesi, St Arneault and Holland,
1971). Cormack (1970), however, work-
ing with Walker 256 tumour in rats attri-
buted the increased survival rates of rats
receiving enzyme treated tumour cells to
their reduced attachment to the meso-
thelial membrane. He ruled out neur-
aminidase-induced increase in immuno-
genicity as an explanation for the reduced
lethality among the recipients to the
neuraminidase treated tumour cells. On
the contrary, he concluded that neuramini-
dase treatment renders the tumour cells
less antigenic.
It is obvious from the present results
that the in vitro incubation of 105 L 1210
cells with VCN at a concentration of
50 u/ml or 15 ,ig/ml ofCPN for a period of
30 min was sufficient to retard the tumour
development significantly in the peritoneal
cavities of normal recipients. The fact
that following implantatioin, the enzyme
treatedtumour cells in immunosuppressive
treated mice showed uninhibited growth
supports the assumption that the in vitro
treatment with the enzyme neuraminidase
does not influence the viability, nor any
regression in the malignant state of the
treated tumour cells, and that the dis-
appearance of the treated tumour cells in
normal mice is due to immunological host
factors. Apparently there exists a lethal
effect on the enzyme treated cells in the
peritoneal cavity of the normal IDBA/2
mice and as a consequence of this the
treated tumour cells disappear totally
from the peritoneal cavity of the mice
within 4-6 days. Recent in vitro studies
have suggested the existence of heat-labile
factor(s) in the normal sera of some, but
not all, mouse strains which are capable of
exerting a cytotoxic effect on neuramini-
dase treated but not oIn untreated tumourK. K. SETHI AND H. BRANDIS
cells (Sanford and Condington, 1971;
Sethi and Brandis, 1972). Working with
lymphoid cells Ray, Gewurz and Simmons
(1-971) have demonstrated increased cyto-
lysis of VCN treated cells by complement.
It wouild seem unlikely, however, that the
in vivo destruction of enzvme treated
L 1210 cells is brought about by mechan-
ism(s) which involves the participation of
the whole complement system since the
iDBA/2 strain of mice has a complement
deficienicy (Rosenberg and Tachibana,
1962).
Bagshawe and Cturrie (1968) reported
that mice surviving primary i.p. implant
of VCN treated L 1210 cells developed
immutnity to subsequent i.p. challenge
with untreated leukaemia cells. How-
ever, the immunity obtained was rela-
tivelv weak, since the mice could not be
protected against a challenge dose of more
than 8 x 103 tuimour cells. In the pre-
sent study we have been able to demon-
strate that the recipients of enzyme
treated L 1210 cells become refractory not
only to i.p. challenge but also to sub-
cutaneous implants of this leukaemia.
This suggests that the evoked immunity
was not local in the sense that it is con-
fined to the organ which had been previ-
ously implanted with enzyme treated cells.
The specificity of the induced immune
response is indicated by the fact that the
mice were unable to reject a low i.p.
challenge dose of EAT cells. It is also
obvious that mice surviving an i.p. implant
of 105 L 121 0 cells preincubated with
50 u/ml of VCN or 15 ,ug/ml of CPN for
either 30 or 60 min proved completely
immune to subsequent challenge inocula
of 103 or 105 leukaemia cells. However,
the immune response induced by L 1210
cells preincubated with 250 u/ml of VCN
or 35 /ig/ml of CPN for 60 min failed to
arrest the growth of a challenge dose of 105
L 1210 cells although protection was
achieved against 103 L 1210 cells. Con-
ceivably the preincubation of L 1210 cells
with high neuraminidase concentrations
for prolonged periods resulted in the
destruction of the immunogenic capacity
of the leukaemia cells (Bekesi et al., 1971).
The failure ofBagshawe and Currie (1968)
to achieve protection of mice which sur-
vived a primary injection of VCN treated
L 1210 cells against challenge doses higher
than 8 x 103 could be attributable to the
reduced immunogenicity of the enzyme
treated L 1210 cell preparations as a
result of incuibation with a high VCN
concentration, i.e. 500 u/2 X 106 cells/ml
for 30 min.
Judging from the results of the experi-
ments carried out in an attempt to transfer
the immunity from the mice which had
received the enzyme treated L 1210 cells
to normal DBA/2 mice, it appears that the
immune responses evoked by enzyme
treated L 1210 cells were both humoral
and cellular. Passive transfer of im-
munity was successfully achieved by i.p.
administration of serum obtained from
donors which had been implanted with
enzyme treated tumour cells 21 days
before. The serum collected from donors
which had received the enzyme treated
L 1210 cells 2 months previously, how-
ever, was not effective in preventing the
growth of 103 L 1210 cells. Adoptive
transfer of immunity was also achieved by
PE cells from animals which had received
enzyme treated tumour cells. This type
of transfer was, however, effective as late
as 2 months after the donors had received
enzyme treated L 1210 cells. Since the
PE cell population used in transfer experi-
ments consisted mainly of macrophages
(85-90%), it implies that macrophages
were the effector cells in the rejection of
the tumour. It may be mentioned,
however, that strictly speaking the trans-
fer of immunity by PE cells does not
exclude the participation of humoral anti-
bodiesintherejectionphenomenonbecause
of the possible presence of antibody form-
ing cells among the transferred population
and/or the role of cytophilic antibody(ies)
at the surface of the macrophages.
Furthermore, in spite of its strain speci-
ficity a weak immune response against
L 1210 leukaemia has been reported to
exist in DBA/2 mice (Mihich, 1969) and as
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such the co-operation of this host defence
response, which is relatively inefficient per
se in the rejection of L 1210 leukaemia
cells observed in our transfer experiments,
cannot be completely ruled out. It is not
yet known whether a qualitative difference
exists between the immune response trans-
ferred by the serum and that transferred
by PE cells.
Thus, whereas the results ofthe present
study suggest that neuraminidase treat-
ment oftumour cells results in an increase
intheir immunogenicity, itis alsoclearthat
prolonged treatment with higher enzyme
concentrations can abolish the immuno-
genic capacity ofthe treated preparations.
The nature of immunogen(s) involved and
the exact mode oforigin ofhighly immuno-
genic L 1210 cells following neuraminidase
treatment is still obscure.
Whatever the nature of the immuno-
gen(s) involved may be, neuraminidase
treatment appears to be an effective pro-
cedure for producing " attenuated " vac-
cines for an otherwise susceptible host.
The possible use of such " attenuated "
tumour vaccines in the immunotherapy of
cancer is obvious. In preliminary un-
published experiments we have been able
to reduce successfully the incidence of
lethality due to advanced L 1210 leu-
kaemia, and have also achieved a signifi-
cant prolongation in the life span of
leukaemic mice by repeated interdermal
injections of neuraminidase treated living
leukaemia cells and also by neuraminidase
treated membrane preparations of this
leukaemia cell type.
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